QQ客服 官方微博 反馈留言

浏览/检索结果: 共5条，第1-5条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 PTK2-mediated degradation of ATG3 impedes cancer cells susceptible to DNA damage treatment 期刊论文 AUTOPHAGY, 2017 Ma, Ke; Fu, Wan; Tang, Ming; Zhang, Chaohua; Hou, Tianyun; Li, Ran; Lu, Xiaopeng; Wang, Yanan; Zhou, Jingyi; Li, Xue; Zhang, Luyao; Wang, Lina; Zhao, Ying; Zhu, Wei-Guo 收藏  |  浏览/下载：10/0  |  提交时间：2017/12/03 ATG3  cancer therapy  mitotic catastrophe  PTK2  tyrosine phosphorylation  FOCAL ADHESION KINASE  MITOTIC CATASTROPHE  AUTOPHAGOSOME FORMATION  OVARIAN-CANCER  TUMOR-GROWTH  FAK  CONJUGATION  CARCINOMA  PATHWAYS  DEATH   Synthesis and Biological Activities of New Halophenols 期刊论文 2013, 卷号: 9, 期号: 2, 页码: 303-311 作者:  Zheng, FeiLang;  Ban, ShuRong;  Feng, XiuE;  Zhao, ChengXiao;  Du, GuanHua 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/13 Halophenols  furan-2-yl(phenyl)methanone  protein tyrosine kinase (PTK) inhibitor  vascular smooth muscle cell (VSMC) proliferation inhibitor  Structure-activity relationships (SAR)   The Marine-Derived Oligosaccharide Sulfate (MdOS), a Novel Multiple Tyrosine Kinase Inhibitor, Combats Tumor Angiogenesis both In Vitro and In Vivo 期刊论文 PLOS ONE, 2008, 卷号: 3, 期号: 11 作者:  Ma, Jingui;  Xin, Xianliang;  Meng, Linghua;  Tong, Linjiang;  Lin, Liping 收藏  |  浏览/下载：14/0  |  提交时间：2019/01/08 Naturally occurring homoisoflavonoids function as potent protein tyrosine kinase inhibitors by c-Src-based high-throughput screening 期刊论文 JOURNAL OF MEDICINAL CHEMISTRY, 2008, 卷号: 51, 期号: 15, 页码: 4419-4429 作者:  Lin, Li-Gen;  Xie, Hua;  Li, Hong-Lin;  Tong, Lin-Jiang;  Tang, Chun-Ping 收藏  |  浏览/下载：12/0  |  提交时间：2019/01/08 Antitumor activity of a new N-substituted thiourea derivative, an EGFR signaling-targeted inhibitor against a panel of human lung cancer cell lines 期刊论文 CHEMOTHERAPY, 2008, 卷号: 54, 期号: 6, 页码: 463-474 作者:  Xiong, Xishan;  Liu, Hong;  Fu, Lili;  Li, Lin;  Li, Jian 收藏  |  浏览/下载：33/0  |  提交时间：2019/01/08 EGFR  tyrosine kinase inhibitor  non-small-cell lung cancer  IC50  Erk1/2  AKT